Diagnostik des hepatozellulären Karzinoms

Zusammenfassung

Risikofaktoren und Symptome des hepatozellulären Karzinoms (HCC): Eine Leberzirrhose aufgrund von Infektionen mit dem Hepatitis-B- oder -C-Virus oder Alkoholabusus ist Hauptrisikofaktor für die Entstehung eines hepatozellulären Karzinoms. Das Fehlen von spezifischen Symptomen erschwert die frühzeitige Diagnosestellung. Screening von Patienten mit Leberzirrhose: Der gebräuchlichste Tumormarker in der Diagnostik des HCCs ist das Alpha-Fetoprotein (AFP). Der Nutzen anderer serologischer Marker wie zum Beispiel des Des-gamma-carboxy-prothrombins (DGCP) oder Fraktionen des AFPs (AFP-L3) werden in diesem Zusammenhang diskutiert. Ultraschalluntersuchungen der Leber sollten bei Patienten mit Leberzirrhose alle 6 (- 12) Monate durchgeführt werden. Überwachung der solitären Raumforderung in der Zirrhoseleber: Die Sonografie stellt die häufigste bildgebende Methode in der Detektion des hepatozellulären Karzinoms dar, wobei in der Literatur sehr unterschiedliche Sensitivitäten für die Methode angegeben werden. Sonografisch kann ein HCC echoarm, echogleich zum übrigen Lebergewebe oder echoreich imponieren, es kann rundlich oder oval sein und sich glatt oder unregelmäßig abgrenzen. Farbdoppler- und powerdopplersonografisch zeigen sich irregulär verlaufende, intratumorale Gefäßsignale. In der Differenzialdiagnose kleinerer maligner Raumforderungen in der zirrhotischen Leber ist die Kontrastmittelsonografie hilfreich. Die Computertomografie (CT) und die Magnetresonanztomografie (MRT) mit und ohne Kontrastmittel spielen sowohl in der Diagnostik als auch im Stagingprozess des HCCs eine wichtige Rolle. Zur definitiven Diagnosesicherung ist gegebenenfalls die Histologie nötig. Vorgehen bei bekanntem HCC: Verschiedene Tumormarker werden in der Beurteilung der Tumorprogression und zur Einschätzung von Prognose und Therapieerfolg eingesetzt. Unter verschiedenen Stagingsystemen des hepatozellulären Karzinoms stellt das „Barcelona-Clinic-Liver-Cancer (BCLC) staging system” derzeit das einzige Stagingsystem dar, welches neben dem Tumorstadium auch Parameter der Leberfunktion, den Allgemeinzustand des Patienten und weitere, tumorassoziierte Symptome berücksichtigt. Was die Therapieoptionen des HCCs angeht, spielen neben der Tumorresektion auch nicht chirurgischen Behandlungsmethoden wie die perkutane Ethanolinjektion (PEI), die Radiofrequenzablation (RFTA) oder die transarterielle Chemoembolisation (TACE) eine Rolle. Diese lokal ablativen Verfahren kommen bei ausgewählten Patienten mit HCC auch zur Überbrückung bis zur orthotopen Lebertransplantation zum Einsatz. Die Kontrastmittelsonografie ermöglicht die Kontrolle der lokalen Ablationserfolge.

Abstract

Risk factors and symptoms of hepatocellular carcinoma (HCC): The main risk factors of HCC include infection with hepatitis B or C virus, as well as alcohol consumption. There are no specific symptoms of HCC, making early diagnosis and detection of the disease difficult. When HCC presents with specific clinical symptoms, the tumour is typically very far advanced. Surveillance in liver cirrhosis: The most common serological marker used in HCC diagnosis is alpha-fetoprotein (AFP), but other tumour markers such as the des-gamma-carboxyprothrombin (DGCP) or fractions of AFP (AFP-L3) exist and there use is discussed in this context. Surveillance should be done by sonography at 6 (to 12) months intervals. The single nodule in the cirrhotic liver: Ultrasound is the most commonly used imaging modality for detecting HCC tumour nodules with a large range of reported sensitivities. HCC may appear as a hypoechoic, isoechoic, or hyperechoic round or oval lesion with intratumoural flow signals on Doppler or power Doppler sonography. The differentiation of smaller malignant lesions in cirrhotic livers can be improved by contrast-enhanced ultrasound (CEUS). Spiral computed tomography (CT) and magnetic resonance imaging (MRI) with and without contrast enhancement play an important role in the diagnosis and staging of HCC. If the vascular pattern on imaging is not typical, biopsy becomes necessary. The patient with known HCC: Different tumour markers are used in the evaluation of tumour progression, prediction of patient outcome and treatment efficacy. Among the various staging systems used in the context of HCC, the Barcelona-Clinic-Liver-Cancer (BCLC) staging system is currently the only staging system that takes into account tumour stage, liver function, physical status and cancer-related symptoms. Beside surgical resection, non-surgical treatments such as percutaneous ethanol injection (PEI), radiofrequency thermoablation (RFTA) and trans-arterial chemoembolisation (TACE) are used. Successful tumour “bridging” with ablative therapy methods can be achieved in carefully selected patients on the waiting list for orthotopic liver transplantation. Contrast-enhanced sonography is able to control the ablation treatment of HCC.

Leber - HCC - Diagnostik

liver - HCC - diagnostics

Literatur

• 1 Bosch F X, Ribes J, Diaz M. et al . Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127 5-16
• 2 Tangkijvanich P, Mahachai V, Suwangool P. et al . Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma.  World J Gastroenterol. 2004;  10 1547-1550
• 3 Bruix J, Sherman M, Llovet J M. et al . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference.  J Hepatol. 2001;  35 421-430
• 4 Giordano T P, Kramer J R, Souchek J. et al . Cirrhosis and heptatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992 - 2001.  Arch Intern Med. 2004;  164 2349-2354
• 5 Gish R G. Hepatocellular carcinoma: overcoming challenges in disease management.  Clin Gastroenterol Hepatol. 2006;  4 252-261
• 6 Llovet J M. Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound.  Clin Gastroenterol Hepatol. 2006;  4 29-35
• 7 Farinati F, Marino D, De Giorgio M. et al . Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither?.  Am J Gastroenterol. 2006;  101 524-532
• 8 Daniele B, Bencivenga A, Megna A S. et al . α-fetoprotein and ultrasonography screening for hepatocellular carcinoma.  Gastroenterology. 2004;  127 108-112
• 9 Pateron D, Ganne N, Trinchet J C. et al . Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.  J Hepatol. 1994;  20 65-71
• 10 Peterson M S, Baron R L. Radiologic diagnosis of hepatocellular carcinoma.  Clin Liver Dis. 2001;  5 123-144
• 11 Liu W C, Lim J H, Park C K. et al . Poor sensitivity of sonography in detection of hepatocellular carcinoma in advanced liver cirrhosis: accuracy of pretransplantation sonography in 118 patients.  Eur Radiol. 2003;  13 1693-1698
• 12 Zhang B H, Yang B H. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer.  J Med Screen. 1999;  6 108-110
• 13 Zhang B H, Yang B H, Tang Z Y. Randomized controlled trial of screening for hepatocellular carcinoma.  J Cancer Res Clin Oncol. 2004;  130 417-422
• 14 Trevisani F, De N S, Rapaccini G. et al . Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).  Am J Gastroenterol. 2002;  97 734-744
• 15 Bruix J, Sherman M. Management of hepatocellular carcinoma.  Hepatology. 2005;  42 1208-1236
• 16 Lencioni R, Cioni D, Della Pina C. et al . Imaging diagnosis.  Semin Liver Dis. 2005;  2 162-170
• 17 Lencioni R, Pinto F, Armillotta N. et al . Assessment of tumor vascularity in hepatocellular carcinoma: comparison of power Doppler US and color Doppler US.  Radiology. 1996;  201 353-358
• 18 Rickes S, Schulze S, Neye H. et al . Improved diagnosing of small hepatocellular carcinomas by echo-enhanced power Doppler sonography in patients with cirrhosis.  Eur J Gastroenterol Hepatol. 2003;  15 893-900
• 19 Tanaka S, Ioka T, Oshikawa O. et al . Dynamic sonography of hepatic tumors.  AJR Am J Roentgenol. 2001;  177 799-805
• 20 D’Onofrio M, Martone E, Pozzi Mucelli R. Contrast-enhanced ultrasonography (CEUS) in the screening of patients affected by chronic liver disease/cirrhosis.  Poster Presentation 13th United European Gastroenterology Week, Copenhagen. 2005; 
• 21 Quaida E, Calliada F, Bertolotto M. et al . Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence.  Radiology. 2004;  232 420-430
• 22 Gaiani S, Celli N, Piscaglia F. et al . Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography.  J Hepatol. 2004;  41 421-426
• 23 Rickes S, Ocran K, Schulze S. et al . Evaluation of Doppler sonographic criteria for the differentiation of hepatocellular carcinomas and regenerative nodules in patients with liver cirrhosis.  Ultraschall Med. 2002;  23 83-90
• 24 Bhartia B, Ward J, Guthrie J A. et al . Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue.  Am J Roentgenol. 2003;  180 577-584
• 25 Lutz A M, Willmann J K, Goepfert K. et al . Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.  Radiology. 2005;  237 520-528
• 26 Kim Y K, Kwak H S, Kim C S. et al . Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT.  Radiology. 2006;  238 531-541
• 27 Stoker J, Romijn M G, Man R A. et al . Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection off hepatocellular carcinoma.  Gut. 2002;  51 105-107
• 28 Colli de A, Fraquelli M, Casazza G. et al . Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systemic review.  Am J Gastroenterol. 2006;  101 513-523
• 29 Caturelli E, Solmi L, Anti M. et al . Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study.  Gut. 2004;  53 1356-1362
• 30 Caturelli E, Biasini E, Bartolucci F. et al . Diagnosis of hepatocellular carcinoma complicating liver cirrhosis: utility of repeat ultrasound-guided biospy after unsuccessful first sampling.  Cardiovasc Intervent Radiol. 2002;  25 295-299
• 31 Bolondi L, Benzi G, Santi V. et al . Relationship between alpha-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a western population.  Ital J Gastroenterol. 1990;  22 190-194
• 32 Toyoda H, Kumada T, Kiriyama S. et al . Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma.  Clin Gastroenterol Hepatol. 2006;  4 111-117
• 33 Koike Y, Shiratori Y, Sato S. et al . Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.  Cancer. 2001;  91 561-569
• 34 Yan P, Yan L N. Staging of hepatocellular carcinoma.  Hepatobiliary Pancreat Dis Int. 2003;  2 491-495
• 35 Marrero J A, Fontana R J, Barrat A. et al . Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an american cohort.  Hepatology. 2005;  41 707-716
• 36 Bigourdan J M, Jaeck D, Meyer N. et al . Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation.  Liver Transpl. 2003;  9 513-520
• 37 Giangregorio F, Aragona G, Marinone M. et al . Clinical utility of contrast-enhanced US (CEUS) for the control of loco-regional treatments of HCCs.  Poster Presentation 13th United European Gastroenterology Week, Copenhagen. 2005; 
• 38 Pompili M, Mirante V G, Rondinara G. et al . Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficiacy at explant analysis and of safety for tumor recurrence.  Liver Transplant. 2005;  9 1117-1126
• 39 Chen Y K, Hsieh D S, Liao C S. et al . Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence.  Anticancer Res. 2005;  25 4719-4725
• 40 Bismuth H, Majno P E, Adam R. Liver transplantation for hepatocellular carcinoma.  Semin Liv Dis. 1999;  19 311-322
• 41 Mazzaferro V, Regalia E, Doci R. et al . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med. 1996;  334 693-699
• 42 Yao F Y, Hirose R, LaBerge J M. et al . A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.  Liver Transplant. 2005;  12 1505-1514
• 43 Peterson M S, Baron R L, Marsh J W Jr. et al . Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation.  Radiology. 2000;  217 743-749
• 44 Maciel A C, Cerski C T, Moreira R K. et al . Hepatocellular carcinoma in patients undergoing orthothopic liver transplantation: radiological findings with anatomopathological correlation in Brazil.  Arq Gastroenterol. 2006;  43 24-29
• 45 Rode A, Bancel B, Douek P. et al . Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver.  J Comput Assist Tomogr. 2001;  25 327-336
• 46 Ledinghen de V, Laharie D, Lecesne R. et al . Detection of nodules in liver cirrhosis: spiral computed tomograpy or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients.  Eur J Gastroenterol Hepatol. 2002;  14 159-165
• 47 Libbrecht L, Bielen D, Verslype C. et al . Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations.  Liver Transp. 2002;  8 749-761
• 48 Macarini L, Marini S, Milillo P. et al . Double-contrast MRI (DC-MRI) in the study of the cirrhotic liver: utility of administering Gd-DTPA as a complement to examinations in which SPIO liver uptake and distribution alterations (SPIO-LUDA) are present and in the identification and characterisation of focal lesions.  Radiol Med (Torino). 2006;  111 1087-1102
• 49 Ruelas-Villavicencio A L, Vargas-Vorackova F. In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective?.  Ann Hepatol. 2004;  3 152-159